Pacira (PCRX)
NASDAQ:PCRX
Want to see PCRX full AI Analyst Report?
PCRX Stock Chart & Stats
$24.72
-$0.08(-0.43%)
At close: 4:00 PM EST
$24.72
-$0.08(-0.43%)
Day’s Range― - ―
52-Week Range$18.80 - $27.64
Previous CloseN/A
Volume54.84K
Average Volume (3M)571.75K
Market Cap
$877.96M
Enterprise Value$1.18B
Total Cash (Recent Filing)$202.18M
Total Debt (Recent Filing)$411.18M
Price to Earnings (P/E)178.5
Beta0.78
Next Earnings
Aug 04, 2026EPS Estimate
0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.12
Shares Outstanding39,334,984
10 Day Avg. Volume454,463
30 Day Avg. Volume571,753
Financial Highlights & Ratios
PEG Ratio-1.53
Price to Book (P/B)1.66
Price to Sales (P/S)1.59
P/FCF Ratio8.44
Enterprise Value/Market Cap1.34
Enterprise Value/Revenue1.61
Enterprise Value/Gross Profit2.02
Enterprise Value/Ebitda9.97
Forecast
1Y Price Target
$28.40Price Target Upside14.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)2.88
Revenue Forecast (FY)$766.64M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthPacira’s sharply reduced leverage and stronger debt-to-equity profile materially increase financial flexibility. A low-debt capital structure supports R&D funding, commercialization investments and share repurchases while lowering interest burden, improving resilience through policy or product-cycle swings.
Cash Generation & MarginsSustained operating and free cash flow plus an ~80% non‑GAAP gross margin point to durable unit economics and manufacturing efficiency for EXPAREL. Strong cash conversion funds pipeline work and buybacks without meaningfully raising leverage, supporting long‑term funding optionality.
Durable Product Franchise & ProtectionEXPAREL’s volume momentum, expanded reimbursement coverage and a larger patent estate (21 Orange Book patents) strengthen market exclusivity and payer access. These structural commercial and IP advantages support sustained unit demand and make generic entry and reimbursement erosion harder over multiple years.
Bears Say
Volatile ProfitabilityEarnings volatility and currently thin operating and net margins limit reliable profitability and return metrics. This inconsistent earnings power constrains reinvestment capacity and raises sensitivity to reimbursement, mix shifts or temporary volume declines, making future cash flow less predictable.
GPO/contracting Pressure On Revenue MixStructural contracting through a third GPO and vial‑mix shifts create persistent pressure on realized revenue per unit despite rising volumes. Sustained GPO discounts can compress margins and make top-line growth less valuable, requiring higher volumes or price/payer wins to maintain revenue growth.
Policy Risk & Elevated Operating SpendThe scheduled 2027 expiration of the NOPAIN policy creates a multi‑year reimbursement risk that could reduce access outside the surgical bundle. Coupled with elevated SG&A and stepped-up R&D spending, this raises structural margin and cash‑burn risk over the next several quarters if policy or commercialization gains stall.
Pacira Pharmaceuticals News
PCRX FAQ
What was Pacira’s price range in the past 12 months?
Pacira lowest stock price was $18.80 and its highest was $27.64 in the past 12 months.
What is Pacira’s market cap?
Pacira’s market cap is $877.96M.
When is Pacira’s upcoming earnings report date?
Pacira’s upcoming earnings report date is Aug 04, 2026 which is in 59 days.
How were Pacira’s earnings last quarter?
Pacira released its earnings results on Apr 30, 2026. The company reported $0.6 earnings per share for the quarter, beating the consensus estimate of $0.548 by $0.052.
Is Pacira overvalued?
According to Wall Street analysts Pacira’s price is currently Undervalued.
Does Pacira pay dividends?
Pacira does not currently pay dividends.
What is Pacira’s EPS estimate?
Pacira’s EPS estimate is 0.65.
How many shares outstanding does Pacira have?
Pacira has 39,334,984 shares outstanding.
What happened to Pacira’s price movement after its last earnings report?
Pacira reported an EPS of $0.6 in its last earnings report, beating expectations of $0.548. Following the earnings report the stock price went down -4.119%.
Which hedge fund is a major shareholder of Pacira?
Currently, no hedge funds are holding shares in PCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pacira Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.40 (14.89% Upside)
$28.40 (14.89% Upside)
Blogger Sentiment
Bullish
PCRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 130.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 13.4%
Last 30 Days ▼ 13.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.92%
12-Months-Change
Fundamentals
Return on Equity
0.73%
Trailing 12-Months
Asset Growth
-23.83%
Trailing 12-Months
Company Description
Pacira
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
PCRX Company Deck
PCRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominately positive picture: the company reported solid top-line momentum across core products (EXPAREL, ZILRETTA, ioverao) with meaningful YoY growth, strengthened IP protection, expanded reimbursement coverage (110M+ covered lives), encouraging pipeline progress with near-term readouts, and healthy adjusted EBITDA and buyback activity. Near-term challenges include revenue mix impacts from a new GPO and winter storms, modest margin compression and elevated SG&A/R&D spending tied to strategic initiatives, and policy timing risk around NOPAIN’s scheduled 2027 expiration. On balance the positives — sustainable product growth, strengthened commercial and IP positions, active pipeline catalysts, and disciplined capital returns — outweigh the lowlights.View all PCRX earnings summariesPCRX Stock 12 Month Forecast
Average Price Target
$28.40
▲(14.89% Upside)
Technical Analysis
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Ownership Overview
3.72% Insiders
25.10% Mutual Funds
21.53% Other Institutional Investors
16.05% Public Companies and
Individual Investors